The Evolving Landscape of Pancreatic Cancer
- 1 January 2023
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 19 (1) , 35-36
Abstract
Commentary on evolving landscape of pancreatic cancer #JOPKeywords
This publication has 6 references indexed in Scilit:
- Pancreatic Adenocarcinoma ManagementJCO Oncology Practice, 2023
- Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2Journal of Clinical Oncology, 2021
- Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC TrialJournal of Clinical Oncology, 2020
- Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic CancerNew England Journal of Medicine, 2019
- Randomized phase II study of second-line modified FOLFIRI with PARP inhibitor ABT-888 (Veliparib) (NSC-737664) versus FOLFIRI in metastatic pancreatic cancer (mPC): SWOG S1513.Journal of Clinical Oncology, 2019
- Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas.Journal of Clinical Oncology, 2018